NeuroPace (NPCE) Cash from Operations Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | 27.41% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 22.38% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 30.85% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 168.71% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | 12.26% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 65.19% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 43.79% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 9.30% |
| 10 | NeuroPace | 462.46 Mn | 410.76 Mn | 18.91 Mn | 3.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.92% |
| Mar 31, 2026 | 15.27% |
| Dec 31, 2025 | 27.31% |
| Sep 30, 2025 | 34.66% |
| Jun 30, 2025 | 42.18% |
| Mar 31, 2025 | 13.03% |
| Dec 31, 2024 | 16.94% |
| Sep 30, 2024 | 26.29% |
| Jun 30, 2024 | 13.41% |
| Mar 31, 2024 | -8.33% |
| Dec 31, 2023 | 19.85% |
| Sep 30, 2023 | 24.76% |
| Jun 30, 2023 | -10.08% |
| Mar 31, 2023 | -14.27% |